{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:15:36Z","timestamp":1783692936547,"version":"3.55.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10,15]]},"DOI":"10.1093\/cid\/cit452","type":"journal-article","created":{"date-parts":[[2013,7,10]],"date-time":"2013-07-10T00:56:29Z","timestamp":1373417789000},"page":"1081-1093","source":"Crossref","is-referenced-by-count":56,"title":["Epidemiology of Pyrazinamide-Resistant Tuberculosis in the United States, 1999\u20132009"],"prefix":"10.1093","volume":"57","author":[{"given":"Ekaterina V.","family":"Kurbatova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Cavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"S. Click","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Peter","family":"Cegielski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,7,9]]},"reference":[{"key":"key\n\t\t\t\t20170623071210_CIT452C1","volume-title":"Drug-resistant tuberculosis: a survival guide for clinicians","author":"Francis","year":"2008","edition":"2nd ed"},{"key":"key\n\t\t\t\t20170623071210_CIT452C2","volume-title":"Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update","author":"World Health Organization","year":"2011"},{"key":"key\n\t\t\t\t20170623071210_CIT452C3","first-page":"1","article-title":"Treatment of tuberculosis","volume":"52","author":"The US Centers for Disease Control and Prevention","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20170623071210_CIT452C4","first-page":"6","article-title":"The curious characteristics of pyrazinamide: a review","volume":"7","author":"Zhang","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20170623071210_CIT452C5","first-page":"796","article-title":"Role of individual drugs in the chemotherapy of tuberculosis","volume":"4","author":"Mitchison","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20170623071210_CIT452C6","first-page":"460","article-title":"A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy","volume":"126","author":"British Thoracic Association","year":"1982","journal-title":"Am Rev Respir Dis"},{"key":"key\n\t\t\t\t20170623071210_CIT452C7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0041-3879(81)90016-7","article-title":"Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. The results up to 30 months","volume":"62","author":"Singapore Tuberculosis Service\/British Medical Research Council","year":"1981","journal-title":"Tubercle"},{"key":"key\n\t\t\t\t20170623071210_CIT452C8","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1128\/AAC.05293-11","article-title":"Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis","volume":"55","author":"Tasneen","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170623071210_CIT452C9","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1128\/AAC.00384-12","article-title":"Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis","volume":"56","author":"Williams","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170623071210_CIT452C10","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0140-6736(12)61080-0","article-title":"14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial","volume":"380","author":"Diacon","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170623071210_CIT452C11","first-page":"748","article-title":"Activation of pyrazinamide and nicotinamide in acidic environments in vitro","volume":"70","author":"McDermott","year":"1954","journal-title":"Am Rev Tuberc"},{"key":"key\n\t\t\t\t20170623071210_CIT452C12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1099\/0022-1317-51-1-42","article-title":"Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide","volume":"51","author":"Zhang","year":"2002","journal-title":"J Med Microbiol"},{"key":"key\n\t\t\t\t20170623071210_CIT452C13","volume-title":"Susceptibility testing of mycobacteria, nocardiae, and other aerobic actimomycets; approved standard. NCCLS document M24-A","author":"NCCLS","year":"2003"},{"key":"key\n\t\t\t\t20170623071210_CIT452C14","volume-title":"Susceptibility testing of mycobacteria, nocardiae, and other aerobic actimomycets; approved standard. NCCLS document M24-A2","author":"NCCLS","year":"2011"},{"key":"key\n\t\t\t\t20170623071210_CIT452C15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1128\/JCM.01775-09","article-title":"Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide","volume":"48","author":"Chedore","year":"2010","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20170623071210_CIT452C16","first-page":"461","article-title":"Pyrazinamide susceptibility and amidase activity of tubercle bacilli","volume":"95","author":"Konno","year":"1967","journal-title":"Am Rev Respir Dis"},{"key":"key\n\t\t\t\t20170623071210_CIT452C17","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nm0696-662","article-title":"Mutations in pncA, a gene encoding pyrazinamidase\/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus","volume":"2","author":"Scorpio","year":"1996","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t20170623071210_CIT452C18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1086\/589240","article-title":"Human tuberculosis due to Mycobacterium bovis in the United States, 1995\u20132005","volume":"47","author":"Hlavsa","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623071210_CIT452C19","first-page":"1075","article-title":"Tuberculosis in humans and animals: an overview","volume":"14","author":"LoBue","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20170623071210_CIT452C20","article-title":"Reported tuberculosis in the United States, 2010","author":"Centers for Disease Control and Prevention","year":"2011"},{"key":"key\n\t\t\t\t20170623071210_CIT452C21","article-title":"Report of verified case of tuberculosis (rvct) instruction manual","author":"US Centers for Disease Control and Prevention"},{"key":"key\n\t\t\t\t20170623071210_CIT452C22","article-title":"Tuberculosis laboratory aggregate report","author":"US Centers for Disease Control and Prevention"},{"key":"key\n\t\t\t\t20170623071210_CIT452C23","volume-title":"Guide to the application of genotyping to tuberculosis prevention and control","author":"National TB Controllers Association\/CDC Advisory Group on Tuberculosis Genotyping.","year":"2004"},{"key":"key\n\t\t\t\t20170623071210_CIT452C24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/cid\/cir788","article-title":"Relationship between Mycobacterium tuberculosis phylogenetic lineage and clinical site of tuberculosis","volume":"54","author":"Click","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623071210_CIT452C25","first-page":"723","article-title":"Tuberculosis genotyping\u2014United States, 2004\u20132010","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20170623071210_CIT452C26","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates","volume":"19","author":"Kim","year":"2000","journal-title":"Stat Med"},{"key":"key\n\t\t\t\t20170623071210_CIT452C27","first-page":"154","article-title":"Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2008 and 2009. A report of the Australian Mycobacterium Reference Laboratory Network","volume":"35","author":"Lumb","year":"2011","journal-title":"Commun Dis Intell"},{"key":"key\n\t\t\t\t20170623071210_CIT452C28","first-page":"571","article-title":"Trend of anti-tuberculosis drug resistance in Korea, 1994\u20132004","volume":"11","author":"Bai","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20170623071210_CIT452C29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/1471-2180-10-223","article-title":"Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand","volume":"10","author":"Jonmalung","year":"2010","journal-title":"BMC Microbiol"},{"key":"key\n\t\t\t\t20170623071210_CIT452C30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5588\/ijtld.11.0266","article-title":"Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis","volume":"16","author":"Pierre-Audigier","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20170623071210_CIT452C31","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1128\/JCM.00973-08","article-title":"Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates","volume":"46","author":"Mphahlele","year":"2008","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20170623071210_CIT452C32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.5588\/ijtld.10.0739","article-title":"Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea","volume":"16","author":"Kim","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20170623071210_CIT452C33","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/1471-2334-11-240","article-title":"Characteristics of pncA mutations in multidrug-resistant tuberculosis in Taiwan","volume":"11","author":"Chiu","year":"2011","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20170623071210_CIT452C34","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1093\/jac\/dkm054","article-title":"Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong","volume":"59","author":"Chan","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170623071210_CIT452C35","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1128\/JCM.43.7.3530-3532.2005","article-title":"Does resistance to pyrazinamide accurately indicate the presence of Mycobacterium bovis?","volume":"43","author":"de Jong","year":"2005","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20170623071210_CIT452C36","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1128\/JCM.39.2.647-650.2001","article-title":"Pyrazinamide-monoresistant Mycobacterium tuberculosis in the United States","volume":"39","author":"Hannan","year":"2001","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20170623071210_CIT452C37","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/thoraxjnl-2012-201824","article-title":"Ethnicity and mycobacterial lineage as determinants of tuberculosis disease phenotype","volume":"68","author":"Pareek","year":"2013","journal-title":"Thorax"},{"key":"key\n\t\t\t\t20170623071210_CIT452C38","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S1473-3099(07)70108-1","article-title":"Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development","volume":"7","author":"Gagneux","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20170623071210_CIT452C39","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1128\/JCM.05435-11","article-title":"Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide","volume":"50","author":"Simons","year":"2012","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20170623071210_CIT452C40","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1128\/JCM.06479-11","article-title":"Performance of tuberculosis drug susceptibility testing in U.S. laboratories from 1994 to 2008","volume":"50","author":"Angra","year":"2012","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20170623071210_CIT452C41","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1128\/AAC.01550-10","article-title":"Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis","volume":"55","author":"Campbell","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170623071210_CIT452C42","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/jac\/dkl231","article-title":"A new rapid and simple colorimetric method to detect pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide","volume":"58","author":"Martin","year":"2006","journal-title":"J Antimicrob Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/57\/8\/1081\/17853070\/cit452.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T07:31:27Z","timestamp":1503473487000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/cit452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,9]]},"references-count":42,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,7,9]]},"published-print":{"date-parts":[[2013,10,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cit452","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7,9]]}}}